BioCryst Pharmaceuticals has reported positive results from the extension phase of its randomised Phase IIb study of BCX4208 added to allopurinol in patients with gout.
BCX4208, a once-daily oral dosing xanthine oxidase inhibitor, has been studied in more than 500 patients as an add-on therapy to address unmet medical needs in patients with gout.
The 24-week blinded safety extension trial confirmed that BCX4208 was safe and well-tolerated, and sustained serum uric acid control over time in patients who had failed to reach the therapeutic goal of <6mg/dl of serum uric acid on allopurinol alone.
In the study, vaccines were administrated at either 16 or 20 weeks of treatment, and responses were evaluated by measuring changes in antibody titres four weeks later.
In the original 12-week study, 279 patients were randomised. Later, 160 patients entered the extension phase and were given BCX4208 at daily doses of 5mg, 10mg, 20mg or 40mg, or a placebo. Allopurinol 300 mg once-daily was administered in all study arms.
The extended Phase IIb study showed that patients generated healthy immune responses to a vaccine challenge at 16 or 20 weeks of BCX4208 treatment, and BCX4208 added to allopurinol was found safe and well-tolerated at all doses studied.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below formBy GlobalData
The study demonstrated that response rates to tetanus toxoid and polyvalent pneumococcal vaccine in patients treated with BCX4208 were similar to placebo-treated patients who received tetanus toxoid and pneumococcal vaccine.
Following 24 weeks of treatment, BCX4208 daily doses of 5mg, 10mg, 20mg and 40mg showed response rates of 40%, 50%, 46% and 55% respectively, compared with 25% for placebo.
BioCryst Pharmaceuticals senior vice-president and chief medical officer William Sheridan said that the sustained efficacy, healthy immune responses to the vaccines and a clean safety profile from 900 patient-months of drug exposure form the basis for Phase III trials.
"Based on these results, we have selected the 5mg, 10mg and 20mg doses of BCX4208 for further evaluation," Sheridan said.
Image caption: Gout is a medical condition characterised by recurrent attacks of acute inflammatory arthritis- a red, tender, hot, swollen joint (Photo credit: James Heilman).